Catalent, Inc. (CTLT): Price and Financial Metrics


Catalent, Inc. (CTLT): $138.27

0.01 (+0.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTLT POWR Grades


  • CTLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 85.88% of US stocks.
  • The strongest trend for CTLT is in Momentum, which has been heading down over the past 47 weeks.
  • CTLT's current lowest rank is in the Value metric (where it is better than 32.98% of US stocks).

CTLT Stock Summary

  • CTLT has a market capitalization of $23,334,660,328 -- more than approximately 88.71% of US stocks.
  • The price/operating cash flow metric for Catalent Inc is higher than 91.42% of stocks in our set with a positive cash flow.
  • Over the past twelve months, CTLT has reported earnings growth of 113.45%, putting it ahead of 82.2% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Catalent Inc are BR, AME, STLD, ADM, and LDOS.
  • Visit CTLT's SEC page to see the company's official filings. To visit the company's web site, go to www.catalent.com.

CTLT Valuation Summary

  • CTLT's price/sales ratio is 5.6; this is 50.66% lower than that of the median Healthcare stock.
  • CTLT's price/sales ratio has moved up 4.3 over the prior 86 months.
  • Over the past 86 months, CTLT's price/sales ratio has gone up 4.3.

Below are key valuation metrics over time for CTLT.

Stock Date P/S P/B P/E EV/EBIT
CTLT 2021-08-31 5.6 5.7 42.1 29.8
CTLT 2021-08-30 5.6 5.7 42.1 29.8
CTLT 2021-08-27 5.9 6.0 44.5 31.6
CTLT 2021-08-26 5.9 6.0 44.7 31.7
CTLT 2021-08-25 5.9 5.9 44.3 31.4
CTLT 2021-08-24 5.7 5.8 43.3 30.8

CTLT Growth Metrics

  • The year over year revenue growth rate now stands at 30.81%.
  • Its 2 year net income to common stockholders growth rate is now at 74.16%.
  • Its 2 year revenue growth rate is now at 19.93%.
Over the past 33 months, CTLT's revenue has gone up $1,526,700,000.

The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 3,998 433 529
2021-03-31 3,757.4 471.4 496.8
2020-12-31 3,464.7 518.1 291.5
2020-09-30 3,275.3 564.8 249.2
2020-06-30 3,094.3 440.3 173
2020-03-31 2,872.4 355.5 109.2

CTLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTLT has a Quality Grade of C, ranking ahead of 38.58% of graded US stocks.
  • CTLT's asset turnover comes in at 0.469 -- ranking 96th of 677 Pharmaceutical Products stocks.
  • HSKA, SPPI, and INSM are the stocks whose asset turnover ratios are most correlated with CTLT.

The table below shows CTLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.469 0.338 0.131
2021-03-31 0.459 0.332 0.129
2020-12-31 0.447 0.323 0.086
2020-09-30 0.451 0.322 0.082
2020-06-30 0.456 0.318 0.073
2020-03-31 0.449 0.315 0.058

CTLT Stock Price Chart Interactive Chart >

Price chart for CTLT

CTLT Price/Volume Stats

Current price $138.27 52-week high $142.64
Prev. close $138.26 52-week low $79.65
Day low $137.38 Volume 558,095
Day high $138.82 Avg. volume 952,019
50-day MA $123.55 Dividend yield N/A
200-day MA $111.85 Market Cap 23.61B

Catalent, Inc. (CTLT) Company Bio


Catalent provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The company was founded in 2007 and is founded in Somerset, New Jersey.


CTLT Latest News Stream


Event/Time News Detail
Loading, please wait...

CTLT Latest Social Stream


Loading social stream, please wait...

View Full CTLT Social Stream

Latest CTLT News From Around the Web

Below are the latest news stories about Catalent Inc that investors may wish to consider to help them evaluate CTLT as an investment opportunity.

Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SOMERSET, N.J., September 07, 2021--Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021.

Yahoo | September 7, 2021

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tues...

Benzinga | September 3, 2021

Contract Manufacturing of Injectable Drugs Market to See Huge Growth by 2027 | Lonza, Catalent, Jubilant Life Sciences

Latest published market study on Global Contract Manufacturing of Injectable Drugs Market provides an overview of the current market dynamics in the Contract Manufacturing of Injectable Drugs space, as well as what our survey respondentsall outsourcing decision-makerspredict the market will

OpenPR | September 1, 2021

Catalent Q4 Results Beat Estimates; Announces $1B Bettera Acquisition

Catalent (CTLT) reported better-than-expected fiscal Q4 and 2021 results for the period ended June 30, 2021. The company said that it has reached an agreement to acquire Bettera Holdings, a manufacturer in the nutritional supplements market, for $1 billion. Catalent is a global provider of drug delivery technologies and manufacturing solutions. Fiscal Q4 2021 revenues increased 25% year-over-year to $1.19 billion, surpassing the consensus estimate of $1.14 billion. Additionally, Q4 adjusted net income was $209 million compared to $154 million reported in the same quarter last year. Furthermore, EPS was $1.16 compared to $0.90 reported in the same quarter last year and above consensus estimates of $1.03.

Neha Gupta on TipRanks | August 31, 2021

Biopharmaceuticals Manufacturing Consumables Testing Market Forecast & Opportunities, 2028 | Alcami Corporation, Merck KGaA, Eurofins Scientific, Catalent, Inc, Avomeen, BioSpectra, Inc

Biopharmaceuticals manufacturing consumables analytical testing is necessary to support a biopharmaceutical product from discovery to development through clinical trials to manufacture and marketing. Consumables are important materials that are utilised in the production process or come into contact with the

OpenPR | August 31, 2021

Read More 'CTLT' Stories Here

CTLT Price Returns

1-mo 14.59%
3-mo 27.31%
6-mo 30.43%
1-year 64.27%
3-year 224.81%
5-year 440.33%
YTD 32.86%
2020 84.85%
2019 80.56%
2018 -24.10%
2017 52.37%
2016 7.71%

Continue Researching CTLT

Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:

Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0141 seconds.